A5083215789- Colorectal Cancer Screening and Detection
- Gastric Cancer Management and Outcomes
- Genetic factors in colorectal cancer
- Diverticular Disease and Complications
- Global Cancer Incidence and Screening
- Economic and Financial Impacts of Cancer
- Pharmaceutical Practices and Patient Outcomes
- Mycobacterium research and diagnosis
- Health Systems, Economic Evaluations, Quality of Life
- Diabetes Management and Research
- Esophageal Cancer Research and Treatment
- Myasthenia Gravis and Thymoma
- Advances in Oncology and Radiotherapy
- Colorectal and Anal Carcinomas
- Colorectal Cancer Treatments and Studies
- Cerebral Venous Sinus Thrombosis
- Metabolism, Diabetes, and Cancer
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Healthcare Systems and Reforms
- Microscopic Colitis
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Ophthalmology and Eye Disorders
- Parkinson's Disease and Spinal Disorders
- COVID-19 and healthcare impacts
- Cancer Genomics and Diagnostics
Myovant Sciences (United States)
2024-2025
Exact Sciences (United States)
2020-2024
Okinawa Prefectural Chubu Hospital
2023
Sanofi (United States)
2018-2020
Austin College
2018-2020
Texas College
2018-2020
American Medical Research
2018-2020
University of Nebraska Medical Center
2018-2020
University of Arkansas for Medical Sciences
2020
Midwestern University
2020
Importance Noninvasive stool-based screening tests (SBTs) are effective alternatives to colonoscopy. However, a positive SBT result requires timely follow-up colonoscopy (FU-CY) complete the colorectal cancer paradigm. Objectives To evaluate FU-CY rates after and assess association of early COVID-19 pandemic with rates. Design, Setting, Participants This mixed-methods cohort study included retrospective analysis deidentified administrative claims electronic health records data between June...
<h3>Importance</h3> Colorectal cancer (CRC) screening reduces CRC incidence and mortality. It is important to examine patterns over time, including after the introduction of new modalities. <h3>Objective</h3> To compare use tests before availability multitarget stool DNA (mt-sDNA) test, given that endorsed options have changed. <h3>Design, Setting, Participants</h3> This longitudinal cohort study used administrative claims data in 2 discrete periods: (August 1, 2011, July 31, 2014) 2016,...
Objective Real-world data regarding colorectal cancer (CRC) screening adherence and use of various modalities is critical to improving efficacy CRC prevention programs. We assessed overall rates utilization by modality over a three-year period (2017-2019) within large Primary Care network.
Colorectal cancer is the second leading cause of cancer-related mortality in adults United States. Despite compelling evidence improved outcomes colorectal cancer, screening rates are not optimal. This study aimed to characterize trends over last two decades and assess impact various modalities on overall rates. Using National Health Interview Survey data from 2005 2021, we examined [colonoscopy, multitarget stool DNA (mt-sDNA), fecal occult blood test (FOBT)/fecal immunochemical test,...
This economic evaluation examines whether adult patients in the US who have commercial or Medicare insurance pay out-of-pocket costs associated with follow-up colonoscopy within 6 months of a noninvasive stool-based test.
Colorectal cancer (CRC) is the second most deadly in USA. Early detection can improve CRC outcomes, but recent national screening rates (62%) remain below 80% goal set by National Cancer Roundtable. Multiple options are endorsed for average-risk screening, including multi-target stool DNA (mt-sDNA) test. We evaluated cross-sectional mt-sDNA test completion a population of commercially and Medicare-insured patients.
Abstract Purpose This study examined adherence to screening for fecal immunochemical test (FIT). Methods Adults (≥ 50–75) with a FIT between 1/1/2014 and 6/30/2019 in MarketScan administrative claims were selected (index = earliest FIT). Patients followed 10 years pre- 3 post-index. at increased risk CRC or prior excluded. Year over year was measured Results Of 10,253 patients, the proportion adherent repeat testing 2 23.4% 10.6% 3. 76.6% not 2, 5.4% Conclusion suggest tests is poor,...
To identify predictors of hypoglycemia and five other clinical economic outcomes among treated patients with type 2 diabetes (T2D) using machine learning structured data from a large, geographically diverse administrative claims database. A retrospective cohort study design was applied to Optum Clinformatics indexed on first antidiabetic prescription date. hypothesis-free, Bayesian analytics platform (GNS Healthcare REFS™: Reverse Engineering Forward Simulation) used build ensembles...
Colorectal cancer (CRC) is a leading cause of mortality in the United States. Outcomes are greatly improved if CRC detected early; hence, screening currently recommended for adults aged 45 years and older at average risk disease. Despite this recommendation availability accurate tests, rates below those recommended. The goal study was to identify temporal trends (from 2015 2019) utilization tests detection among average-risk individuals within St Elizabeth Healthcare system Kentucky, primary...
Aims: To evaluate total costs and health consequences of a colorectal cancer (CRC) screening program with colonoscopy, fecal immunochemical tests (FIT), expanded use multitarget stool DNA (mt-sDNA) from the perspectives Integrated Delivery Networks (IDNs) payers in United States.Materials methods: We developed budget impact cost-consequence model that simulates CRC for eligible 50- to 75-year-old adults. A status quo scenario an increased mt-sDNA were modeled. The includes current mix...
Colorectal cancer (CRC) is the third leading cause of death in US. Early detection improves CRC outcomes and multiple options are endorsed for screening; however, adherence remains challenging. Among Medicaid enrollees, fecal immunochemical test (FIT) often used average-risk screening, with suboptimal rates reported (12.3-23.2 %). The navigation-supported (personalized outreach by phone, mail, email text), at home collection, multi-target stool DNA (mt-sDNA) represents a relatively recent...
To assess patient and primary care provider (PCP) factors associated with adherence to American Cancer Society (ACS) United States Preventive Services Task Force (USPSTF) guidelines for average risk colorectal cancer (CRC) screening.Retrospective case-control study of medical pharmacy claims from the Optum Research Database 01/01/2014 - 12/31/2018. Enrollee sample was adults aged 50 75 years ≥ 24 months continuous health plan enrollment. Provider PCPs listed on average-risk patients in...
Guidelines include several options for average-risk colorectal cancer (CRC) screening that vary in aspects such as invasiveness, recommended frequency, and precision. Thus, patient provider preferences can help identify an appropriate strategy. This study elicited CRC of physicians individuals at average risk (IAR).IAR aged 45-75 years licensed (primary care or gastroenterology) completed online discrete choice experiment (DCE). Participants were recruited from representative access panels...
Descriptive study focusing on real-world utilization and characteristics of men with prostate cancer tested the 17-gene Genomic Prostate Score® (GPS™) assay by linking administrative claims electronic health record (EHR) data GPS results.
While colorectal cancer (CRC) is the second leading cause of cancer-related mortality in United States (US), outcomes can be improved through timely screening. Despite benefits and widespread availability screening tests, adherence to recommended strategies low. The study aimed provide recent evidence regarding rates recommendations among adults at average risk for CRC a commercially insured Medicare Advantage population. De-identified administrative data from large US research database were...
Effective colorectal cancer (CRC) screening requires proper adherence beginning at the recommended age. For those with positive results on stool-based tests (SBTs), a follow-up colonoscopy is warranted. The objectives of this study were to 1) examine initial rates after turning 50 years old; and 2) assess SBT.This retrospective used de-identified administrative claims data from 01/01/2006 06/30/2020 for commercially insured Medicare Advantage enrollees. objective 1, index year was enrollees...
To investigate the impact of treatment intensification (TI) on glycaemic outcomes in patients with type 2 diabetes glycated haemoglobin A1c (A1C) ≥7% after ≥6 months oral antidiabetes drugs (OADs) or basal insulin (BI).Data were extracted from Optum administrative claims database 1 January 2009 to 31 August 2015. Patients TI ≤6 first A1C (index date) compared no (NTI). included addition OAD, GLP-1 receptor agonist premixed OAD and BI cohorts, and/or bolus cohort increasing dose cohort....
While prevalence of up-to-date screening status is the usual reported statistic, annual incidence may better reflect current clinical practices and more actionable. Our main purpose was to examine incident colorectal cancer (CRC) rates in Medicare beneficiaries explore characteristics associated with CRC screening.Using 20% random sample data, study population included 2016-2018 fee-for-service covered by Parts A B aged 66-75 years at average risk. For each year, we excluded individuals who...
Colorectal cancer screening rates are important metrics for public health and quality indicators care systems; however, published estimates of colorectal often include both high-risk average-risk patients, the use different epidemiologic methods makes between-study comparisons tenuous. The objective this study was to measure proportion American adults who up date with guidelines examine impact evaluation on rate estimates. This repeated cross-sectional used administrative claims identify...
AMCP Nexus 2018: Preparing for the Next Generation of Care in Orlando, Florida, is expected to attract more than 2,400 managed care pharmacists and other health professionals who manage evaluate drug therapies, develop networks, work with medical managers information specialists improve all individuals enrolled programs. The Abstracts program provides a forum through which authors can share their insights outcomes advanced practice. Poster author presentations 2018 are scheduled Wednesday,...
Introduction/Objectives: Despite compelling evidence of clinical and economic benefits, adherence to colorectal cancer (CRC) screening remains low. Increasing public awareness through various outreach methods may improve uptake. The objective this study was evaluate the uptake non-invasive multi-target stool DNA (mt-sDNA) by different in an average-risk employer population. Methods: This retrospective observational included CRC screening-eligible individuals aged ≥50 years insured...
35 Background: Earlier colorectal cancer diagnosis can improve patient outcomes, but the payer cost impact of earlier stage at is not well understood because information directly available in administrative claims data. This data gap impairs researchers’ ability to fully evaluate financial neoplasia detection resulting from screening. In prior work, we used SEER-Medicare develop machine learning algorithms assign AJCC stages colon (CC) and rectal (RC) patients using treatment flags derived...